A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
Recruiting · NCT03530852 · Registry updated 2026-08-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB | Digestive System Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, digestive system disorder, intestinal disorder, malabsorption syndrome, metabolic disease, short bowel syndrome | Recruiting | Not applicable | 2026-08-03 | NCT03530852 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Alcresta Therapeutics, Inc. | 5 |
| Boston Children's Hospital | 238 |
| Food and Drug Administration (FDA) | 31 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Boston Children's Hospital | Boston | United States | 343 |
| Children's Hospital Los Angeles | Los Angeles | United States | 226 |